Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.
Zacks.com on MSN17h
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...
Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback